Spots Global Cancer Trial Database for oropharynx
Every month we try and update this database with for oropharynx cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer | NCT01066741 | Oropharynx Canc... Hypopharynx Can... | Homeodent® 1.4% Sodium Bic... | 18 Years - 85 Years | Centre Leon Berard | |
| Pembrolizumab in Combination With CRT for LA-SCCHN | NCT02586207 | Head and Neck C... Squamous Cell C... Oral Cavity Can... Oropharynx Canc... Hypopharynx Can... Larynx Cancer Laryngeal Cance... | pembrolizumab (... Cisplatin Radiation | 18 Years - | Sanford Health | |
| Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) | NCT06056310 | Head and Neck C... | Xevinapant Cisplatin intensity-modul... | 18 Years - | EMD Serono | |
| Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx) | NCT04696744 | Circulating Tum... Oropharyngeal C... | CTC detection | 18 Years - | Hospices Civils de Lyon | |
| Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer | NCT00094081 | Head and Neck N... | tirapazamine (S... cisplatin Radiation Thera... | 18 Years - | Sanofi | |
| De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca | NCT01530997 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin Limited surgica... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor | NCT00377247 | Primary Advance... Squamous Cell C... | autologous mono... | 37 Years - | University of Pittsburgh | |
| EValuating the Safety Of De-escaLated Head and Neck Irradiation in HPV positivE Oropharynx Cancer in Non-smokers/Minimal Smokers | NCT03777384 | Oropharyngeal C... | 18 Years - | Sanford Health | ||
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | NCT05386550 | Head and Neck C... | Xevinapant (Deb... IMRT Placebo | 18 Years - | EMD Serono | |
| Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx) | NCT04696744 | Circulating Tum... Oropharyngeal C... | CTC detection | 18 Years - | Hospices Civils de Lyon | |
| A New Delineation Approach for Oral Cavity, Oropharynx, Larynx and Hypopharynx in IMRT for Head and Neck Cancer | NCT05539144 | Head and Neck C... Radiotherapy Oropharynx Abno... Radiotherapy; A... | "Oropharyngeal ... oropharynx oropharynx and ... | - | Hebei Provincial Hospital of Traditional Chinese Medicine | |
| Optimising Radiation Therapy in Head and Neck Cancers Using Functional Image-Guided Radiotherapy and Novel Biomarkers | NCT04242459 | Head and Neck C... | Adaptive Radiot... | 18 Years - 70 Years | Royal Marsden NHS Foundation Trust | |
| P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC | NCT03077243 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin (or a... Assessment for ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | NCT00100789 | Head and Neck C... | gemcitabine paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Study to Evaluate the Natural History of Head and Neck Cancer Precursors in Taiwan | NCT02017288 | Head and Neck N... | 21 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck | NCT02158234 | Squamous Cell C... | Cisplatin Stereotactic Bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Post-Market Clinical Trial for Access and Visualization of the Oropharynx, Hypopharynx and Larynx During Transoral Procedures | NCT02262247 | OSA Oral Disease Oropharyngeal N... Hypopharyngeal ... | 22 Years - | Medrobotics Corporation | ||
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | NCT05386550 | Head and Neck C... | Xevinapant (Deb... IMRT Placebo | 18 Years - | EMD Serono | |
| Evaluation of an Active Swallowing Rehabilitation on Quality of Life of Patients Treated by Radiotherapy for Head and Neck Cancer | NCT02892487 | Cancer of Head ... | Swallowing ther... | 18 Years - | Rennes University Hospital | |
| The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | NCT01706939 | Squamous Cell C... | Reduced Dose Ra... Standard Dose R... Carboplatin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck | NCT02158234 | Squamous Cell C... | Cisplatin Stereotactic Bo... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A New Delineation Approach for Oral Cavity, Oropharynx, Larynx and Hypopharynx in IMRT for Head and Neck Cancer | NCT05539144 | Head and Neck C... Radiotherapy Oropharynx Abno... Radiotherapy; A... | "Oropharyngeal ... oropharynx oropharynx and ... | - | Hebei Provincial Hospital of Traditional Chinese Medicine | |
| P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC | NCT03077243 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin (or a... Assessment for ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. | NCT04648020 | Chemoradiothera... | Clonidine HCl M... Placebo Mucoadh... | 18 Years - | Monopar Therapeutics | |
| Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN | NCT01884259 | Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... | Docetaxel Cisplatin 5-fluorouracil Cetuximab Induc... Cetuximab Radio... Boost irradiati... | 18 Years - 75 Years | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | NCT04564989 | Oropharyngeal S... Carcinoma, Squa... Head and Neck S... Oropharynx Squa... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Phase II Trial of Allovectin-7® for Head and Neck Cancer | NCT00050388 | Head and Neck C... Squamous Cell C... Head and Neck N... Carcinoma of th... | Allovectin-7® | 18 Years - | Vical | |
| Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) | NCT06056310 | Head and Neck C... | Xevinapant Cisplatin intensity-modul... | 18 Years - | EMD Serono | |
| Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT01427205 | Head and Neck C... | Cetuximab OSI-906 Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| Robotic Surgery in the Seated Position for Benign and Malignant Lesions of the Head and Neck | NCT02792322 | Oropharyngeal N... Head and Neck C... | Transoral Robot... | 18 Years - 90 Years | Mayo Clinic | |
| The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | NCT01706939 | Squamous Cell C... | Reduced Dose Ra... Standard Dose R... Carboplatin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Dysphagia Assessment After Swallowing Sparing RadioTherapy | NCT03448341 | Cancer of Oroph... Cancer of Nasop... | 18 Years - 80 Years | Azienda Ospedaliero, Universitaria Pisana | ||
| Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer | NCT00101582 | Mucositis Solid Tumors Stomatitis Head and Neck C... Squamous Cell C... | Placebo palifermin cisplatin chemo... Radiotherapy | 18 Years - | Swedish Orphan Biovitrum | |
| Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients | NCT02926573 | Head and Neck C... Acute Pain Postoperative P... | Gabapentin Placebo | 18 Years - | Washington University School of Medicine | |
| Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck | NCT01287390 | Primary Non-ope... Primary Non-ope... Primary Non-ope... Primary Non-ope... | video fluorosco... extra imaging scoring acute t... scoring of late... scoring quality... | 18 Years - | University Hospital, Ghent | |
| De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca | NCT01530997 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin Limited surgica... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck | NCT01921426 | Squamous Cell C... Squamous Cell C... | GC4419 | 18 Years - | Galera Therapeutics, Inc. | |
| Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design | NCT02128906 | Squamous Cell C... | Cisplatin IMRT Docetaxel Cetuximab | 18 Years - | University of Pittsburgh | |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer | NCT04590963 | Squamous Cell C... | Monalizumab Cetuximab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Evaluation of an Active Swallowing Rehabilitation on Quality of Life of Patients Treated by Radiotherapy for Head and Neck Cancer | NCT02892487 | Cancer of Head ... | Swallowing ther... | 18 Years - | Rennes University Hospital | |
| Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer | NCT00094081 | Head and Neck N... | tirapazamine (S... cisplatin Radiation Thera... | 18 Years - | Sanofi | |
| Symptom Burden in Head and Neck Cancer | NCT01219673 | Head And Neck C... | Placebo Armodafinil Minocycline Bupropion | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer | NCT01706939 | Squamous Cell C... | Reduced Dose Ra... Standard Dose R... Carboplatin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design | NCT02128906 | Squamous Cell C... | Cisplatin IMRT Docetaxel Cetuximab | 18 Years - | University of Pittsburgh | |
| OraTest in Combination With Visual Examination and Visual Examination Alone | NCT00537199 | Head And Neck C... Oropharynx Canc... | Visual Examinat... OraTest | 45 Years - | M.D. Anderson Cancer Center | |
| Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | NCT04564989 | Oropharyngeal S... Carcinoma, Squa... Head and Neck S... Oropharynx Squa... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Interventional Study Collecting Quantitative and Qualitative Data About Patient With Non Treated Cancer | NCT01647477 | Upper Aerodiges... | interview questionnaires | 18 Years - | Centre Oscar Lambret | |
| S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | NCT00100789 | Head and Neck C... | gemcitabine paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer | NCT01066741 | Oropharynx Canc... Hypopharynx Can... | Homeodent® 1.4% Sodium Bic... | 18 Years - 85 Years | Centre Leon Berard | |
| ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer | NCT02002182 | Head and Neck C... Squamous Cell C... HPV Positive Or... | ADXS11-001 (ADX... | 18 Years - | Baylor College of Medicine | |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer | NCT04590963 | Squamous Cell C... | Monalizumab Cetuximab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Robotic Surgery in the Seated Position for Benign and Malignant Lesions of the Head and Neck | NCT02792322 | Oropharyngeal N... Head and Neck C... | Transoral Robot... | 18 Years - 90 Years | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
